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Abstract
Background: Fitness costs imposed on bacteria by antibiotic resistance mechanisms are believed to hamper their
dissemination. The scale of these costs is highly variable. Some, including resistance of Staphylococcus aureus to the
clinically important antibiotic mupirocin, have been reported as being cost-free, which suggests that there are few
barriers preventing their global spread. However, this is not supported by surveillance data in healthy communities,
which indicate that this resistance mechanism is relatively unsuccessful.
Results: Epistasis analysis on two collections of MRSA provides an explanation for this discord, where the mupirocin
resistance-conferring mutation of the ileS gene appears to affect the levels of toxins produced by S. aureus when
combined with specific polymorphisms at other loci. Proteomic analysis demonstrates that the activity of the secretory
apparatus of the PSM family of toxins is affected by mupirocin resistance. As an energetically costly activity, this
reduction in toxicity masks the fitness costs associated with this resistance mutation, a cost that becomes apparent
when toxin production becomes necessary. This hidden fitness cost provides a likely explanation for why this
mupirocin-resistance mechanism is not more prevalent, given the widespread use of this antibiotic.
Conclusions: With dwindling pools of antibiotics available for use, information on the fitness consequences of the
acquisition of resistance may need to be considered when designing antibiotic prescribing policies. However, this
study suggests there are levels of depth that we do not understand, and that holistic, surveillance and functional
genomics approaches are required to gain this crucial information.
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Background
Antibiotic resistance, which can involve either the muta-
tion of existing genes or the acquisition of genes encod-
ing a resistance mechanism [1], can evolve in many ways
and frequently incurs a fitness cost to the organism [2].
As antibiotics are most commonly used for short and
defined periods of time, resistant bacteria are under
selection to reduce these costs to avoid displacement
once treatment has finished. In many cases this is
achieved through compensatory mutations that allow
many resistance mechanisms to be stably maintained in
populations for long periods of time [3]. However, some
antibiotic resistance mechanisms have been reported to
incur no detectable fitness costs [4–7], which suggests there
should be no barriers to their widespread dissemination.
Staphylococcus aureus is an example of a major human
pathogen [8] that has become more challenging to treat
due to the emergence of antibiotic resistance, with
methicillin-resistant S. aureus (MRSA) being the most
notable example [9]. S. aureus resides asymptomatically
as part of the normal nasal flora of up to 50% of humans
[10]; however, this carriage is a significant risk factor for
infection [11] to the extent that carriers are often
decolonised using antibiotics such as mupirocin prior to
invasive procedures, including surgery and dialysis [12].
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Mupirocin is a polyketide antibiotic that is applied as an
ointment to eradicate nasal carriage of MRSA in patients
at risk of infection [13]. Such decolonisation has been
reported to reduce S. aureus infections of post-surgical
wounds by 58%, of haemodialysis patients by 80% and of
peritoneal dialysis patients by 63% [14].
The molecular target for mupirocin is the bacterial
isoleucyl-tRNA synthetase (IleRS), which charges tRNAs
with the amino acid isoleucine (Ile) [13]. By binding to
this enzyme the antibiotic halts protein synthesis, and in
doing so inhibits bacterial growth [15]. As a conse-
quence of the widespread use of mupirocin, resistance
has emerged where the bacteria have mutated the gene
encoding IleRS, ileS, resulting in an amino acid substitu-
tion (e.g. V588F, encoded by a G to T single nucleotide
polymorphism (SNP) at position 1762 in the ileS gene
(G1762 T)) that alters the structure of the protein’s
active site without removing its functionality, rendering
mupirocin less effective [16]. This confers a low to inter-
mediate level of resistance on the antibiotic [17]. Alterna-
tively, the bacteria may acquire an alternative IleRS,
encoded by a mupA or mupB gene, on a plasmid, which
confers a higher level of resistance to mupirocin [18, 19].
The prevalence of mupirocin resistance varies widely,
with the highest rates associated with patient groups re-
peatedly exposed to the antibiotic [20, 21]. It has also
been shown that in countries where restrictions were
put in place limiting the use of this antibiotic, such as
New Zealand and Australia, the prevalence of resistant
strains significantly declined [21]. This suggests that
antibiotic exposure is required to maintain selection of
this resistance mechanism within a population, despite it
being reported as incurring no fitness cost.
The ileS gene is highly conserved across the thousands
of sequenced S. aureus isolates, and many failed at-
tempts to inactivate it suggest its activity is essential to
the bacteria. It is therefore surprising that the mutation
that confers mupirocin resistance, by altering the struc-
ture of the encoded protein, does not appear to affect fit-
ness [4]. Particularly given that the replacement of valine
588 with phenylalanine (V588F), a much bulkier residue,
is likely to fill and distort the Rossman fold of the en-
zyme, which is responsible for its ATP binding activity
[4, 16]. However, in a recent genome-wide association
study (GWAS) on the major hospital acquired MRSA
clone, ST239, this mutation was significantly associated
with differences in the virulence of S. aureus isolates
[22]. Its effect on toxin secretion, a major aspect of S.
aureus virulence, was believed to result from epistatic
interactions between ileS and other polymorphic loci.
Upon analysis of a second genetically and geographically
distinct collection of clinical isolates of the USA300
lineage, we detected this epistasis signal again. Here we
characterise the effect this mutation has on both toxin
production and bacterial fitness and in doing so uncover
a potential explanation for the lack of success of these
resistant strains.
Results and discussion
Validation of the epistatic association between mupirocin
resistance and toxicity
We have previously identified toxicity-associated, epistatic
interactions occurring between the mupirocin resistance
(mupR)-conferring SNP in the ileS gene (G1762 T, which
confers the V588F change in the protein) and other poly-
morphic loci within a collection of ST239 MRSA isolates
[22]. As the gold standard for validating any GWAS result
is to demonstrate the same effect in a subsequent inde-
pendent population, we analysed the toxicity and se-
quence data for a collection of 130 USA300 (ST8) MRSA
isolates [23]. The epistasis test within the whole genome
association analysis toolset PLINK [24] compares the tox-
icity of isolates with each allele of a specific locus (i.e.
those with and without a SNP) in combination with each
allele identified at all other loci within the collection, i.e. it
tests whether the co-occurrence of SNPs in any two loci is
significantly associated with a phenotype. With this ap-
proach we found that within this second genetically and
geographically distinct collection of clinical isolates the
SNP conferring mupR resistance emerged again as the
most dominant toxicity-affecting epistatically interacting
locus (Fig. 1), verifying our initial results with the ST239
MRSA collection.
The epistatic signal between the mupR mutation and other
loci appears to be indirect
Epistatic signals can emerge from population-based
GWAS analyses for several reasons. It might signal that
direct interactions are occurring between two loci, such
that together they affect a phenotype, for example a
transcriptional regulator and the region of DNA it binds
to. SNPs can arise in the DNA binding region that affect
how the regulator binds to it, or the regulator might
acquire SNPs that affect its ability to bind the DNA. As
these loci evolve and mutate an epistatic signal associ-
ated with the polymorphisms and the phenotype they
affect could emerge. Alternatively, the epistatic effect
may be a less direct lineage-specific effect, where a
polymorphism can have an effect on a phenotype in one
genetic background but not in another. In this case the
polymorphisms that are associated epistatically with the
primary SNP of interest may simply reflect the iso-
late’s genetic background. To examine whether the
mupR-conferring SNP has a direct or indirect epistatic
effect, we compared the list of loci it was epistatically
paired with from the ST239 and the USA300 collec-
tions (Additional file 1: Table S1). Other than the
mupR-conferring SNP, no other loci were in common
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between the two collections, suggesting that the epi-
static effect may be indirect.
To examine whether the mupR-conferring epistatic
effect was dependent upon a strain’s genetic background,
we introduced it into three distinct S. aureus strains that
all belonged to the ST8 clonal background (as determined
by MLST: SH1000, RN6390B and USFL34). The presence
of the V588F-conferring mutation and the mupR pheno-
type were confirmed; however, it was only in the SH1000
background that any effect on toxicity was observed,
where the mupirocin-resistant strain, MY40, lysed only
71% of the cells (cultured THP-1 cells) compared to the
wild-type mupirocin-sensitive SH1000 strain, which lysed
87% of the cells (n = 6, two-tailed t-test; p = 0.023; the
effect of this mutation was further confirmed in four more
independently selected mupirocin-resistant isolates of the
SH1000 background (Additional file 1: Figure S1). By
comparison, this mupR mutation had no effect on toxicity
in either the RN6390B or USFL34 backgrounds (n = 6;
two-tailed t-test p = 0.59 and 0.12, respectively). Together
these data suggest that the mupR-associated epistatic
effect observed here is likely to be indirect and its effect
on toxicity limited to specific genetic backgrounds.
The effect of mupR on toxicity is independent of the Agr
quorum sensing system
Given the effect on toxicity the mupR-conferring SNP
has in the SH1000 S. aureus strain, we quantified the
levels of production of some of the major cytolytic
toxins produced by S. aureus: alpha toxin and the phe-
nol soluble modulins (PSMs). For this, we first con-
firmed that no other toxicity-affecting mutations had
arisen during our selection of the MY40 (SH1000 mupR)
strain by comparing the genome sequences of the
SH1000 and MY40 strains. The only non-synonymous
SNP difference found between these strains was that
conferring the V588F change in IleRS, although a small
number of synonomous SNP differences were also
detected (Additional file 1: Table S2).
To quantify alpha toxin production, the bacteria were
grown for 18 h and the proteins in supernatant precipi-
tated using trichloroacetic acid, followed by western
blotting using anti-alpha toxin antibodies. For PSM quan-
tification butanol was used to extract the PSMs from the
bacterial supernatant, which were then run on SDS-PAGE
gels. We found that the wild-type mups strain SH1000
produced, on average, twofold more alpha toxin and
3.4-fold more PSMs compared to the mupR mutant strain
(n = 6, two-tailed t-test, p = 0.02 and 0.001, respectively; a
representative image is presented in Fig. 2a), which ex-
plains the results of the THP-1 lysis assay.
Given the dominant effect the Agr quorum regulatory
system has on toxin production, we hypothesised that its
activity may be affected in the mupR mutant. To test this
we quantified RNAIII expression levels, an effector mol-
ecule of the Agr system; no difference in expression was
Fig. 1 Epistasis between the mupirocin resistance-encoding mutation in the ileS gene and many other loci is associated with the toxicity of the
USA300 lineage of MRSA. This heat map illustrates where specific combinations of the polymorphic site in the ileS gene and polymorphic sites
elsewhere on the chromosome are associated with the toxicity of individual isolates. The mupR-conferring site is indicated on the x- and y-axes
by the red arrows
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detected (n = 6, two-tailed t-test, p = 0.49). We also
quantified the response of the mupR and mupS strains to
exogenous AIP, the autoinducing pheromone of the Agr
system, and we quantified how much AIP the mupR and
mupS strains produced. However, we could detect no
difference in Agr activity between theses strains by any
of these assays (Additional file 1: Figure S2), suggesting
that the effect of mupR on toxicity is independent of the
Agr system.
Mupirocin resistance exerts a pleiotropic effect on the S.
aureus proteome
The protein synthesis-disrupting effect of mupirocin has
been used to induce and study the stringent response in
bacteria [25]. Exposure to mupirocin has also been
shown to affect the expression of enzymes involved in
the biosynthesis of other branched chain amino acids
(BCAA) and the CodY virulence regulon [26]. As the
activity of the Agr system does not appear to be affected
by mupR, we hypothesised that this mutation may have a
similar effect on S. aureus that exposure to mupirocin has,
which might explain its effect on toxicity. To examine this
we adopted a proteomic approach using tandem-mas-
s-tagging (TMT) protein mass spectroscopy [27] on whole
cell lysates. As toxin production by S. aureus is growth
dependent, we harvested proteins during the stationary
phase of growth, and where the effect of exposure to
mupirocin was being sought, we used a concentration of
mupirocin that was below the minimum inhibitory con-
centration (MIC) to avoid any confounding effects of
growth repression. The proteins were therefore extracted
from triplicate 18-h cultures in tryptone soy broth (TSB),
where we used a concentration of 10 ng/ml mupirocin,
which we found to be the highest concentrations of
mupirocin for which we found no inhibition of growth of
the mupS SH1000 strain.
Of the 3026 open reading frames predicted for the
NCTC8325 chromosome (which is the closest reference
genome to SH1000), we detected and quantified 1284
proteins, and we used a cut-off of a minimum of a 50%
difference in protein abundance to identify differentially
produced proteins. When we compared the proteomes
of SH1000 and MY40, 135 proteins were differentially
produced (Additional file 2: Table S3), suggesting that
this resistance mutation has pleiotropic effects on pro-
tein production. Exposure of the wild-type SH1000
strain to mupirocin resulted in differential production of
60 proteins when compared to the untreated SH1000
(Additional file 3: Table S4), but the production of only
eight proteins was affected both by mupirocin exposure
and in the mupR mutant (indicated in Additional file 2:
Table S3 and Additional file 3: Table S4), suggesting that
while there are some common downstream effects of
interfering with the activity of IleRS through either mu-
tation or antibiotic exposure, there are many differences
in the outcome.
Interestingly, for both the mupR mutation and expos-
ure to mupirocin we detected an upregulation of IleRS
production, suggesting that the bacteria may be able to
partially compensate for the interference in the activity
a
c d
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Fig. 2 The mupR mutation reduces toxin production by the SH1000 strain. a A representative image of a western blot on TCA precipitated
bacterial supernatant using anti-alpha toxin antibodies. On average we found the wild-type mupS strain produced twofold more alpha toxin
compared to the mupR strain. b Coomassie stained SDS-PAGE gel with butanol extractions of bacterial supernatant, containing the PSMs. On
average we found the wild-type mupS strain produced 3.4-fold more PSM compared to the mupR strain. c Over-expression of the pmtC gene,
which encodes one of the ATP binding proteins of the PSM secretory system, Pmt, in the wild-type SH1000 strain causes a reduction in the
abundance of the PSM in the S. aureus supernatant. An Agr mutant has been provided as a control. d The intra- and extra-cellular levels of PSMs
were pooled to compare the overall levels of PSM production where on average the wild-type strain produced 3.2-fold more PSMs. A full length
SDS-PAGE gel is provided in Additional file 1: Figure S3 to illustrate why we only provide a ‘letter-box’ snap-shot of the gels here
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of this enzyme by upregulating its production. In rela-
tion to previously reported effects on BCAA enzyme
production, induction of the stringent response and
effects on the CodY virulence regulon, the only effect we
observed here was on BCAA enzyme production upon
exposure to mupirocin (Additional file 3: Table S4). We
believe the differences we report here compared to these
previous studies [25, 26] are due to our use of sub-in-
hibitory concentrations of mupirocin and extracting pro-
teins after 18 h, compared to the methodology used in
the other studies where 3× and 5× MICs of mupirocin
were used and the protein extracted within an hour of
this exposure.
Although we detected no effect on the CodY regulon
we did observe a difference between the wild type and
mupR mutant in the abundance of the cytoplasmic re-
sponse regulator of the Agr toxicity regulating system,
AgrA, where the mupR mutant produced, on average,
sevenfold higher levels of this protein (Additional file 2:
Table S3). The agrA and agrC genes are co-transcribed,
but there was no difference in AgrC protein abundance
across the protein preparations, which suggests that the
effect on AgrA abundance must be post-transcriptional.
The AgrA protein needs to be phosphorylated to be-
come transcriptionally active, and as such we would
expect to see increased transcription of the RNAIII
effector molecule of the Agr system were it active. As
mentioned above, however, we detected no difference in
RNAIII expression, which suggests that although AgrA
may be more abundant in the mutant, it does not seem
to be transcriptionally active.
Mupirocin resistance affects the activity of the PSM
secretory apparatus, Pmt
Of the toxins encoded on the SH1000 genome, there
was significantly more of both delta toxin and PSMα1 in
the lysate of the mupirocin-resistant mutant (35- and
21-fold respectively; Additional file 2: Table S3). These
are two of the most abundantly produced members of
the PSM family of cytolytic toxins [28]. This result was
surprising given that our quantification of the levels of
the PSMs in supernatant demonstrated a significantly
lower production by the mupR mutant compared to the
wild-type strain.
As the PSMs are more abundant in the intracellular
environment of the mupR mutant, but less abundant in
the extracellular environment, we hypothesised that PSM
secretion may be affected in the mutant. This is facilitated
by the activity of the PSM export system, Pmt [29], and
although the pmt genes have not been annotated on the
NCTC8325 genome, they are present (locus tags
SAOUHSC_02155, SAOUHSC_02154, SAOUHSC_02153,
SAOUHSC_02152, SAOUHSC_02151). This locus en-
codes a regulatory protein, two membrane bound ABC
transporter proteins and two ATP binding proteins that
fuel the export system, where the four structural genes are
transcribed from a single promoter. Each ATP binding
protein interacts with its paired transporter protein and the
maintained selection of the 1:1:1:1 stoichiometry suggests it
is critical to the exporters activity. In our mupR mutant we
found that there was more than twice as much of one of
the two ATP binding proteins (SAOUHSC_02152, gene
name pmtC) compared with the wild-type strain. We
hypothesised that interference with the stoichiometry of the
proteins in this export system may affect its activity, which
might explain why we find more PSM inside the cell but
less outside. To test this we cloned and expressed the pmtC
gene, from an inducible promoter in the SH1000 wild-type
background, and found that when this ATPase was overex-
pressed it secreted significantly less PSMs into the extracel-
lular environment (2.8-fold difference, n = 6, two-tailed
t-test, p = 0.003; a representative image of this is presented
in Fig. 2c). This suggests that the effect mupirocin resist-
ance has on S. aureus toxicity is at least partially mediated
by interfering with the activity of the PSM secretory
apparatus.
It is interesting to consider that the complete inactiva-
tion of the Pmt system has been shown to be lethal to
the bacteria, presumably as a result of the damage the
PSMs can cause to internal membrane structures [29].
Here we demonstrate a partial blocking of the Pmt sys-
tem by mupirocin resistance, and some accumulation of
PSMs internally; however, as we see no in vitro growth
defects associated with this it must be a sub-toxic level.
Reducing the production of toxins alleviates the fitness
cost of mupR
Toxin production by bacteria is an energetically costly
activity [23, 30, 31]. Although we see a significant reduc-
tion in alpha toxin production by the mupR mutant, for
the PSMs we see an increase in intracellular abundance
but a decrease in the extracellular abundance. This
makes it difficult to speculate on what fitness conse-
quences there might be as a result of these difference.
To clarify this, we compared the total amount (both
intra- and extracellular) of PSMs being produced by the
wild-type and mupR mutant by pooling whole cell lysates
with supernatant prior to performing butanol extrac-
tions. Despite there being more PSMs intracellularly in
the mutant, this represents such a small proportion of
the total amount of PSMs produced by the bacteria that
it had no effect on the relative abundance of the PSMs
(Fig. 2d), demonstrating that the mupR mutant does pro-
duce significantly less of two of the major toxin groups
produced by S. aureus.
The mupR mutation has previously been reported as
having no fitness costs, despite occurring in the active
region of a highly conserved and essential gene [4, 16].
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Here we demonstrate that it has pleiotropic effects on
the S. aureus proteome. As fitness costs associated with
antibiotic resistance can be offset in many ways by
bacteria, we hypothesised that perhaps there is a cost to
becoming mupR, but the associated reduction in the
production of toxins compensates for this. To test this
we performed a series of competition assays to compare
the relative fitness [32] of the mupS and mupR strains in
two genetic backgrounds. As a control we first verified
that reducing toxin production does make a strain rela-
tively more fit when grown in vitro by competing the
mupirocin-sensitive SH1000 against its isogenic Agr mu-
tant, where we found the mutant to be significantly
more fit (Fig. 3a; n = 20, Mann-Whitney U test, p =
0.023). As reported previously, when we competed the
mupS wild strain against the mupR strain we observed
no difference in fitness (Fig. 3a; n = 20, Mann-Whitney
U test, p = 0.15). However, when we quantified the rela-
tive fitness in an Agr defective background where nei-
ther strain could produce toxins, such that any
alleviation of fitness costs that result from the relative
reduction in toxicity of the mupR mutant was nullified,
we found the fitness of the mupR MY41 strain to be
significantly lower than that of the mupS MY18 strain
(Fig. 3a; n = 20, Mann-Whitney U test, p = 0.003). This
demonstrates that this mupirocin resistance-conferring
mutation does incur a fitness cost, but that this cost can
be masked in vitro by reducing the costly production
of toxins.
As the ability to produce toxins is selected for in envi-
ronments such as the skin and nose [23, 33], we
hypothesised that, in such an environment, the costs as-
sociated with this resistance mechanism should become
apparent. To test this we developed a growth medium
with very low levels of nutrients (0.1× TSB) but added
5% horse blood such that strains that can produce toxins
can release and utilise further nutrients from these blood
cells for growth. To avoid the less toxic cells benefiting
from nutrients released by the more toxic bacteria we
grew the wild-type mupS SH1000 strain, an Agr mutant
in the SH1000 background as a control, and MY40, the
SH1000 mupR mutant, separately and quantified their
relative fitness (Malthusians parameters) at 3, 6 and 24 h
in this medium. After 3 h of incubation in the medium
there was no detectable growth of any of the strains;
however, by 6 h all three strains had grown, although the
Agr mutant and the mupR strain grew faster than the
SH1000 strain (Fig. 3b; n = 12, Mann-Whitney U test, p
= 0.003 for the Agr mutant and 0.002 for the mupR mu-
tant). This suggests that the bacteria enter a long lag
phase in this medium, but once adapted (after 3 h) suffi-
cient nutrients are available to sustain some growth. At
this time point the SH1000 strain is at an apparent dis-
advantage, possibly by expending energy on producing
more toxins than the Agr and mupR mutants, although
we would not typically expect S. aureus to produce
toxins this early in its growth phase.
After the 6-h time point there was a distinct shift in
the relative fitness of the strains, with the SH1000 strain
growing faster than the Agr mutant and the mupR strain
(Fig. 3b; n = 12, Mann-Whitney U test, p = 0.018 and
0.01, respectively). The increased relative growth rate of
the wild-type SH1000 strain could be explained by its in-
creased capability to lyse cells and release nutrients ne-
cessary for its growth. To verify this, at the end of the
growth assay we removed the bacteria and intact blood
cells by centrifugation, and quantified by spectroscopy
the levels of haem released from the cells. Significantly
more haem was present in the supernatant of the
SH1000 strain (Fig. 3c; n = 12, Mann-Whitney U test, p
< 0.001 in both cases), demonstrating that SH1000 has
released more cellular material into the broth.
While the relative fitness of any organism is dependent
upon its environment, here we demonstrate how readily
this can fluctuate within an environment. That the
fitness consequences of mupirocin resistance became
apparent when cell lysis became necessary may provide
an explanation for why this resistance-conferring muta-
tion, despite the ease with which it can emerge, is not
more prevalent and is readily lost within healthy com-
munities [21].
Conclusions
Understanding the evolution of antibiotic resistance, in
terms of both how it emerges and how it is stably main-
tained, is critical if ways to curtail its further emergence are
to be developed. With some antibiotic resistance mecha-
nisms being reported as incurring no fitness costs [4–6],
and others where physiological and regulatory compensa-
tion of costs has been demonstrated [23, 31, 33–35], it is
perhaps surprising that they have not become more preva-
lent. Here, by adopting a population-based functional gen-
omics approach, we have uncovered hidden fitness costs
associated with an apparently cost-free, antibiotic resistance
mechanism. We have demonstrated that the mupirocin
resistance-conferring mutation of the gene encoding the
IleRS enzyme has pleiotropic effects on bacteria, which in
hindsight is perhaps unsurprising given the highly con-
served and essential nature of this gene. In this instance,
while reducing the energetic expense associated with toxin
production decreases the resistance-associated fitness costs,
this appears to be unsustainable when the ability to produce
toxins is required. Given that the nose of healthy carriers
has been shown to be such a toxicity-favouring environ-
ment for S. aureus, this toxicity-related fitness off-setting
may explain why this resistance mechanism is not more
prevalent, and is readily displaced, once this antibiotic has
been removed from their environment. An effect we would
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Fig. 3 Mupirocin resistance affects the relative fitness of S. aureus. a The effect of mupR on the relative fitness of S. aureus was determined in strains
with and without a functioning Agr system by direct competition in TSB. There was no difference in fitness in the Agr+ background, but in the
absence of Agr, the mupR strain was less fit. Control competition of an Agr+ vs an Agr− strain is shown. b The effect of mupR on relative fitness was
determined by individual culture in a nutrient-poor environment (0.1× TSB) supplemented with 5% horse blood. At the early stages of growth (0–6 h)
the mupS strain was more fit than both the Agr− and mupR strains. Whereas between 6 and 24 h when the nutrients in the TSB were depleted and
cell lysis became necessary, the mupS strains were relatively more fit than both the Agr− and mupR strains. c After 24 h of growth in the 0.1× TSB + 5%
horse blood medium the Agr+ strain releases more haem into the supernatant relative to the Agr− and mupR strains
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have been unable to explain had we not adopted a popula-
tion-based approach to studying this major bacterial
pathogen.
Methods
Strains and growth conditions
All strains used in this study are listed in Additional file 1:
Table S5. S. aureus strains were grown at 37 °C, in either
tryptic soy agar or broth (TSA/TSB) with the appropri-
ate antibiotic where necessary. The Escherichia coli
TOP10 strain containing the pAgrC(his)A plasmid was
grown in Luria-Bertani (LB) media with 100 μg/ml
ampicillin. THP-1 cells were grown in RPMI 1640 sup-
plemented with foetal bovine serum (10%), L-glutamine
(2 mM), penicillin (100 units/ml) and streptomycin
(100 μg/ml) and incubated at 37 °C with 5% CO2.
Epistasis analysis
Analysis of SNP–SNP epistatic interactions was per-
formed using the “epistasis” option in the PLINK soft-
ware package (http://zzz.bwh.harvard.edu/plink/) [24],
which is based on linear regression analysis and tests the
inclusion of an interaction term (into the regression
equation) for statistical significance. The total number of
non-synonomous SNPs across our collection of 130
USA300 isolates was just under 4000; however, only
those with a minor allele frequency of > 3% were consid-
ered, and as interactions between two SNPs can only be
tested where both coincide, the number of tests per
locus was on average just over 100.
Selection of the mupirocin resistant strain
As an essential gene ileS cannot be inactivated and, as a
consequence, a homologous recombination based muta-
tional approach was unsuccessful. Therefore, to generate
isogenic mupirocin-resistant and -sensitive strains we uti-
lised a selection-based method where 108 bacteria (100 μl
of an overnight culture) on mupirocin containing TSA
plates (4 μg/ml) and on average between two and ten
mupirocin-resistant colonies emerged on each plate after
48 h incubation at 37 °C. Resistant colonies that emerged
were isolated by streaking on fresh antibiotic-containing
plates and mutants with the V588F-conferring mutations
identified by the following mismatch PCR approach. Allele
specific PCR was performed to determine what nucleotide
is present at 1762 of the ileS gene; G results in V588,
which is mupirocin sensitive, and T results in F588, which
confers resistance to mupirocin. Each resistant colony was
screened with three different primer sets:
1. a control set to confirm the presence of the ileS
gene: IleS-F-control and IleS-R
2. a set to determine the presence of a G at position
1762: IleS-F-mupS and IleS-R
3. a set to determine the presence of a T at position
1762: IleS-F-mupR and IleS-R
The reactions were set up as recommended for GoTaq
(Promega) and the cycling conditions were as recom-
mended by the manufacturer; 50.5 °C was used as the an-
nealing temperature and the extension time was 1 min.
Primer
name
Purpose Sequence
IleS-F-
control
Forward control
primer common
to both resistant
and sensitive
bacteria
CTTATAAATTCTTACTTTCTCATGGTTTT
IleS-F-
mupS
Forward primer
matched to the
wild-type mupS
sequence
TAAATTCTTACTTTCTCATGGTTTTGG
IleS-F-
mupR
Forward primer
with two mismatches
which amplifies
the mupR sequence
TAAATTCTTACTTTCTCATGGTTTCT
IleS-R Reverse primer
common to both
resistant and sensitive
bacteria
GATTGGTGCTAACAACTTCGTCATA
Genome sequencing of the mupR strain
S. aureus strain MY40 was sequenced in this study; DNA
was extracted using the QIAamp NA Mini Kit (QIAGEN,
Crawley, UK) using the manufacturer’s instructions with
1.5 μg/μL lysostaphin (Ambi Products LLC, NY, USA) to
facilitate cell lysis. DNA was quantified using a Nanodrop
spectrophotometer, as well as the Quant-iT DNA Assay
Kit (Life Technologies, Paisley, UK) before sequencing.
High-throughput genome sequencing was performed
using a MiSeq machine (Illumina, San Diego, CA, USA)
and the short read, paired-end data were assembled using
the de novo assembly algorithm SPAdes [36]. Sequence
data are archived in the NCBI repositories: GenBank
accession NIPL00000000.1, Short Read Archive (SRA)
SRR5651527, associated with BioProject PRJNA384009.
Assembled genomes are also available on FigShare
(doi.org/10.6084/m9.figshare.5089939.v1).
Toxicity assays
THP-1 cells [37] were grown as described above and
harvested by centrifugation and washed in phosphate
buffered saline (PBS) and diluted to a final density
(determined by haemocytometer) of 2 × 106 cells/ml of
PBS. Bacterial supernatant was harvested after 18 h of
growth in TSB at 37 °C. The bacterial supernatant
(20 μl) was mixed with 20 μl of THP-1 cells and incu-
bated for 12 min at 37 °C. Guava ViaCount (260 μl;
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Milipore) was added to the sample and incubated at
room temperature for 5 min before analysing the viabil-
ity on the Guava flow cytometer (Milipore). Each strain
was assayed six times (three biological replicates and
two technical replicates).
Fitness assays
The strains were cultured individually overnight and
diluted to 104 cfu/ml. For the direct competitions 25 μl
of each diluted culture was added into 5 ml fresh TSB
and grown at 37 °C with shaking for 24 h. The mixed
culture was diluted and plated onto agar plates with and
without 4 μg/ml mupirocin and incubated at 37 °C. The
resulting colonies were counted and the number of
colonies from the mupirocin plate was subtracted from
the count from no antibiotic plate. The Malthusian
parameter was calculated using the following formula:
Ln Final density colony forming units ðCFUð Þ=mlð Þ
=Starting density CFU=mlð ÞÞ
The Malthusian parameters of the mupS and mupR
strains were compared using a Mann-Whitney U test as
the data were not normally distributed. For the individ-
ual fitness assays the strains were cultured overnight,
diluted and added to 0.1× TSB (made with PBS rather
than water to maintain the integrity of the horse blood
cells) to which 5% horse blood (Oxoid) was added. Bac-
terial growth was determined by plating the cultures on
TSA plates after 3, 6 and 24 h of incubation at 37 °C in
air. Each competition was performed between 12 and 20,
either three biological replicates and three technical or
four biological replicates and five technical.
Deletion of the agr locus from SH1000 and MY40
Phage transduction was used to construct the mupR and
mupS Agr mutants. In the S. aureus strain ROJ48, the
entire Agr locus has been replaced with an erythromycin
resistance cassette [38]. This was moved from ROJ48
into SH1000 by phage transduction as follows: ROJ48
ϕ11 lysates were prepared from 200 μl of overnight
ROJ48 culture in LK (1% tryptone, 0.5% yeast extract,
1.6% KCl) which was added to 3 ml of fresh LK and
3 ml of phage buffer (10 mM MgSO4, 4 mM CaCl2,
50 mM Tris-HCl pH 7.8, 100 mM NaCl and 0.1% gel-
atine powder in molecular/MiliQ water), and to this
500 μl ϕ11-RN6390B lysate was added. This was incu-
bated at 30 °C shaking until the media became clear,
which indicated bacterial lysis. The lysates were then fil-
ter sterilised and a second round of lysis was carried out
on ROJ48 with this first round lysate. After these two
lysis steps, transduction into SH1000 and MY40 strains
was performed by adding 200 μl of overnight culture to
1.8 ml LK with 10 μl 1 M CaCl2 and 500 μl the
ϕ11-ROJ48 lysate. This was incubated at 37 °C with
shaking for 45 min; then 1 ml ice-cold 20 mM trisodium
citrate was added and the transducing mixture was
placed on ice for 5 min. The bacteria were harvested by
centrifugation and re-suspended with 1 ml ice-cold
20 mM trisodium citrate. This was incubated on ice for
2.5 h and plated onto TSA plates with 20 mM trisodium
citrate, erythromycin and lincomycin (25 μg/ml), which
was incubated overnight at 37 °C.
qRT-PCR
Overnight cultures were diluted 1:500 into 3 ml fresh
TSB-chloramphenicol. After 18 h of growth 2 ml of this
culture was mixed with 4 ml RNA Protect Bacteria (Qia-
gen), and the RNeasy Mini Kit (Qiagen) was used to
extract RNA following the manufacturer’s protocol.
Lysostaphin (200 μg/ml) was added to Tris-EDTA buffer
(Ambion), and this was added to the sample after the
RNA Protect step before continuing with the protocol.
When the RNA was extracted, a Turbo DNA-free kit
(Thermo) was used to remove genomic DNA from the
RNA samples; 3 μl Turbo DNase was added to the sam-
ple and incubated for 1.5 h at 37 °C, then a further 4 μl
Turbo DNase was added and incubated for 1.5 h. DNase
inactivation reagent (35 μl) was added to the samples to
inactivate the DNase according to the protocol. The
concentration of RNA in the samples was measured
using a Qubit RNA Broad Range Kit (Thermo) and nor-
malised before using a QuantiTect Reverse Transcription
Kit (Qiagen) to convert the RNA samples into cDNA ac-
cording to the manufacturer’s protocol. After adding the
reverse transcriptase, the samples were incubated at 42 °
C for 20 min before raising the temperature to 95 °C for
3 min to inactivate the reverse transcriptase. Primers for
gyrB, a housekeeping gene, were used alongside those
for RNAIII to standardise transcript levels (gyrB forward,
CCAGGTAAATTAGCCGATTGC; gyrB reverse, AAAT
CGCCTGCGTTCTAGAG; RNAIII forward, AGCA
TGTAAGCTATCGTAAACAAC; RNAIII reverse, TTCA
ATCTATTTTTGGGGATG). ssoAdvanced SYBR Green
Supermix (Bio-Rad) was used using a standard curve of
known genomic DNA concentrations for each primer
set. Samples, standards and water (5 μl) were pipetted
into the wells of a 96-well PCR plate. The supermix was
added to water and primers according to the manufac-
turer’s protocol, and 15 μl of this mix was pipetted over
the DNA samples. This was then placed into a qPCR
machine and run using the manufacturer’s recommenda-
tion. The quantity of RNAIII cDNA was divided by the
quantity of gyrB cDNA to get a ratio of RNAIII tran-
scription levels. This was performed six times, three bio-
logical replicates and two technical.
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AIP EC50 and AIP quantification assays
These assays were performed as described previously [38].
Strains were grown overnight in Brain Heart Infusion
(BHI), and 1 ml of the overnight was washed three times
with PBS. The pellet was re-suspended in fresh BHI and
grown for a further 2 h. A dilution series of AIP-1 was
created, with concentrations ranging from 250 to
0.125 nM in 1:2 dilutions, plus 1250 and 2500 nM. The
culture (190 μl) was pipetted into a black 96-well plate,
and 10 μl of this dilution series was also pipetted into the
wells. The OD600 and luminescence readings were carried
out every 15 min for 80 cycles in a Tecan plate reader. For
the AIP quantification strains were grown in BHI with
chloramphenicol (10 μg/ml). The reporter strain was di-
luted 1/20 into fresh BHI and grown for a futher 2 h,
while the supernatants of the mupS and mupR strains were
filtered through a 0.22 μm filter. The reporter strain was
diluted 1/50 and pipetted into a black 96-well plate. The
supernatant was added to the wells at 5% final concentra-
tion, and the OD600 and luminescence readings were car-
ried out every 15 min for 80 cycles in a Tecan plate
reader. This was performed six times, three biological rep-
licates and two technical.
PSM quantification in supernatants
An overnight culture of SH1000 and MY40 was diluted
1:1000 into 50 ml fresh TSB and grown for 18 h. The
cultures were centrifuged at 18,000 rpm for 10 min and
35 ml of the supernatant was mixed with 10 ml butanol.
The samples were incubated at 37 °C shaking for 3 h
and then centrifuged at 3000 rpm for 3 min; 1 ml of the
upper organic layer was taken off. The samples were
then freeze-dried overnight and then re-suspended in
160 μl 8 M urea, separated on an SDS-PAGE gel and
PSMs quantified by densitometry analysis using the Ima-
geJ software. This was performed six times, three bio-
logical replicates and two technical.
TMT labelling and high pH reversed-phase chromatography
Aliquots of 100 μg of up to ten samples per experiment
were digested with trypsin (2.5 μg trypsin per 100 μg
protein; 37 °C, overnight), labelled with Tandem Mass Tag
(TMT) ten plex reagents according to the manufacturer’s
protocol (Thermo Fisher Scientific) and the labelled samples
pooled. An aliquot of the pooled sample was evaporated to
dryness and resuspended in buffer A (20 mM ammonium
hydroxide, pH 10) prior to fractionation by high pH
reversed-phase chromatography using an Ultimate 3000
liquid chromatography system (Thermo Fisher Scientific). In
brief, the sample was loaded onto an XBridge BEH C18 col-
umn (130 Å, 3.5 μm, 2.1 mm × 150 mm, Waters, UK) in
buffer A and peptides eluted with an increasing gradient of
buffer B (20 mM ammonium hydroxide in acetonitrile,
pH 10) from 0 to 95% over 60 min. The resulting fractions
were evaporated to dryness and resuspended in 1% formic
acid prior to analysis by nano-LC MSMS using an Orbitrap
Fusion Tribrid mass spectrometer (Thermo Scientific).
Nano-LC mass spectrometry
High pH RP fractions were further fractionated using an
Ultimate 3000 nanoHPLC system in line with an
Orbitrap Fusion Tribrid mass spectrometer (Thermo
Scientific). In brief, peptides in 1% (vol/vol) formic acid
were injected onto an Acclaim PepMap C18 nano-trap
column (Thermo Scientific). After washing with 0.5%
(vol/vol) acetonitrile 0.1% (vol/vol), formic acid peptides
were resolved on a 250 mm× 75 μm Acclaim PepMap
C18 reverse phase analytical column (Thermo Scientific)
over a 150 min organic gradient, using seven gradient
segments (1–6% solvent B over 1 min, 6–15% B over
58 min, 15–32% B over 58 min, 32–40% B over 5 min,
40–90% B over 1 min, held at 90% B for 6 min and then
reduced to 1% B over 1 min) with a flow rate of
300 nl min− 1. Solvent A was 0.1% formic acid and solv-
ent B was aqueous 80% acetonitrile in 0.1% formic acid.
Peptides were ionised by nano-electrospray ionisation at
2.0 kV using a stainless steel emitter with an internal
diameter of 30 μm (Thermo Scientific) and a capillary
temperature of 275 °C.
All spectra were acquired using an Orbitrap Fusion
Tribrid mass spectrometer controlled by Xcalibur 2.0
software (Thermo Scientific) and operated in data-
dependent acquisition mode using an SPS-MS3 workflow.
FTMS1 spectra were collected at a resolution of 120,000
with an automatic gain control (AGC) target of 200,000 and
a max injection time of 50 ms. Precursors were filtered with
an intensity threshold of 5000 according to charge state (to
include charge states 2–7) and with monoisotopic precursor
selection. Previously interrogated precursors were excluded
using a dynamic window (60s ± 10 ppm). The MS2 precur-
sors were isolated with a quadrupole mass filter set to a
width of 1.2 m/z. ITMS2 spectra were collected with an
AGC target of 10,000, max injection time of 70 ms and CID
collision energy of 35%.
For FTMS3 analysis, the Orbitrap was operated at 50,000
resolution with an AGC target of 50,000 and a max
injection time of 105 ms. Precursors were fragmented by
high energy collision dissociation (HCD) at a normalised
collision energy of 60% to ensure maximal TMT reporter
ion yield. Synchronous precursor selection (SPS) was
enabled to include up to five MS2 fragment ions in the
FTMS3 scan.
Proteomic data analysis
The raw data files were processed and quantified using
Proteome Discoverer software v2.1 (Thermo Scientific) and
searched against the UniProt Staphylococcus aureus strain
NCTC 8325 database using the SEQUEST algorithm [39].
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Peptide precursor mass tolerance was set at 10 ppm and
MS/MS tolerance was set at 0.6 Da. Search criteria
included oxidation of methionine (+ 15.9949) as a variable
modification and carbamidomethylation of cysteine (+
57.0214) and the addition of the TMT mass tag (+ 229.163)
to peptide N-termini and lysine as fixed modifications.
Searches were performed with full tryptic digestion and a
maximum of two missed cleavages were allowed. The re-
verse database search option was enabled and all peptide
data were filtered to satisfy a false discovery rate of 5%.
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